QIAGEN announced the launch of QCI Precision Insights in Europe, with the inclusion of the European Society for Medical Oncology (ESMO) guidelines and European Medicines Agency (EMA) approved oncology drugs catalogue.
QCI Precision Insights is a clinical interpretation service provided by a team of molecular biologists and oncologists who translate molecular data specific to each patient into state-of-the-art clinical insights and therapeutic options. Capable of rapidly interpreting any size panel on any testing platform, QCI Precision Insights now enables molecular pathologists and oncologists in Europe to confidently match complex genomic test data to relevant, geographically-matched treatment options in minutes for evidence-based, individualized treatment recommendations in record time.
“With the growing demand for molecular testing in the clinic, there is a continuous struggle to keep pace. With the finalized integration of N-of-One and their somatic interpretation service into the QCI product line we can now meet this demand,” said Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. “Molecular pathologists can now off-load interpretation work and reduce clinical test interpretation time by as much as 85 percent. So far, over 175,000 oncology cases have been processed by QCI Precision Insights, and I’m excited to see how Europe will embrace this new opportunity to transform the way molecular pathologists intersect with the cancer care continuum.”
The QCI portfolio helps molecular pathologists, oncologists and medical geneticists uncover critical and timely genomics insights for informed and empowered clinical decision making. Connected to QCI Knowledge Base, the platform has processed over 1.6 million molecular profiling cases across somatic and germline indications, giving users access to a rich set of unpublished real-world data for greater precision in trial and treatment matching.
The QIAGEN Knowledge Base is the only manually curated knowledge base in the world supporting over 76,000 disease classes with over 20 million clinical findings and weekly updates to clinical trial registries, approved therapies and published literature.
QCI Precision Insights offers:
Variant/gene-specific information with direct reference to EMA drug approvals and ESMO guidelines
EMA approved drug summaries and approved indications
ESMO clinical practice guidelines
Up-to-date treatments approved by EMA
Demographically relevant European clinical trials
